Product image of Nilotinib Biogaran (Nilotinib) supplied by GNH India

Nilotinib Biogaran

Active Ingredient:
Nilotinib
Origin:
EU

Nilotinib Biogaran (Nilotinib)

Nilotinib, the active ingredient in Nilotinib Biogaran, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It selectively blocks the BCR‑ABL, KIT and PDGFR kinases, reducing malignant cell proliferation, and is approved for Philadelphia chromosome‑positive chronic myeloid leukemia in the chronic phase.

GNH India supplies Nilotinib Biogaran as a licensed, GDP‑compliant international pharmaceutical product, providing reliable access to oncology centres, hospitals and pharmacies worldwide. The company supports regulatory compliance, quality assurance and secure logistics for global procurement.

Manufacturer / TM Owner

Biogaran

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Nilotinib is a tyrosine kinase inhibitor used in the management of Philadelphia chromosome‑positive chronic myeloid leukemia.

  • Chronic myeloid leukemia – chronic phase: reduces disease progression and improves survival.
  • Chronic myeloid leukemia – accelerated phase: may achieve cytogenetic and molecular responses.
  • Chronic myeloid leukemia – blast phase: provides an additional therapeutic option when other TKIs are unsuitable.

How It Works

  • Nilotinib selectively inhibits the BCR‑ABL tyrosine kinase as well as KIT and PDGFR kinases. By binding to the ATP‑binding site of these enzymes, it blocks downstream signaling pathways that drive uncontrolled proliferation of leukemic cells, thereby restoring normal cell growth control.

Side Effects

Adverse reactions to nilotinib vary in frequency and severity.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: loose stools, often transient.
  • Rash: skin erythema or pruritus.
  • Fatigue: generalized tiredness.
  • Myalgia: muscle aches.
  • Headache: mild to moderate intensity.

Serious or Rare Side Effects

  • Cardiovascular events: including arterial occlusive disease.
  • QT interval prolongation: risk of serious arrhythmias.
  • Hepatotoxicity: elevated liver enzymes or hepatitis.
  • Pancreatitis: inflammation of the pancreas.
  • Severe neutropenia: marked reduction in white blood cells.
  • Severe skin reactions: such as Stevens‑Johnson syndrome.

Precautions & Warnings

Nilotinib requires careful monitoring to minimize risks.

  • Monitor blood counts: perform regular CBC to detect cytopenias.
  • Assess cardiac function: baseline ECG and periodic monitoring for QT prolongation.
  • Check liver enzymes: monitor hepatic function during therapy.
  • Avoid strong CYP3A4 inhibitors: concurrent use may increase nilotinib exposure.
  • Store at ambient temperature: keep below 25°C, protect from moisture and light.

Avoid Interactions

Nilotinib can interact with several drug classes, affecting its safety and efficacy.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma concentrations.
  • QT‑prolonging agents (e.g., amiodarone, sotalol): increase risk of arrhythmia.
  • Antacids containing aluminum or magnesium: reduce nilotinib absorption.

Moderate Interactions (Monitor Closely)

  • Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower drug effectiveness.
  • Warfarin: may require more frequent INR monitoring.
  • St. John’s wort: can decrease nilotinib plasma levels.

Frequently Asked Questions

Nilotinib Biogaran is used to treat Philadelphia chromosome‑positive chronic myeloid leukemia (CML). It targets the BCR‑ABL tyrosine kinase that drives the disease, helping to control leukemic cell growth and improve patient outcomes.

Nilotinib binds to the ATP‑binding pocket of BCR‑ABL, KIT and PDGFR kinases, blocking their activity. This inhibition stops downstream signaling that promotes malignant cell proliferation, leading to reduced tumor burden in CML patients.

The specific dose of nilotinib is determined by the prescribing physician based on the patient’s clinical condition, disease phase, and other individual factors. Only a qualified healthcare professional should set the dosing regimen.

Safety data for nilotinib in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a specialist.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any needed import documentation.

Nilotinib belongs to the second‑generation tyrosine kinase inhibitor class and offers higher potency against BCR‑ABL than first‑generation agents such as imatinib. It is often chosen for patients who need a deeper molecular response or who have resistance to earlier TKIs.

Nilotinib should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct light to maintain stability throughout its shelf life.

Nilotinib is taken orally, usually as tablets, with a low‑fat meal to improve absorption. Patients should follow the prescribing physician’s instructions regarding timing, food intake and any necessary dose adjustments.

Serious risks include cardiovascular events such as arterial occlusive disease, QT interval prolongation leading to arrhythmias, severe liver toxicity, pancreatitis, and profound neutropenia. Patients should be monitored regularly for these complications.

Nilotinib is contraindicated in patients with known hypersensitivity to the drug or its excipients, and in those taking strong CYP3A4 inhibitors or medications that significantly prolong the QT interval. Clinicians must evaluate each patient’s medical history before prescribing.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Nilotinib

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT